secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-03-29T23:59:59+00:00
Accession:  0000950170-22-004854
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta appoints manufacturing executive Angela Thedinga to its Board of Directors
--------------------------------------------------------------------------------

- Appointed Angela Thedinga as independent Class I director effective March 28, 2022.
- Received stock option for 32,000 shares vesting in three equal annual installments.
- Will receive annual cash retainer of $40,000, pro-rated for Q1 2022.
- Thedinga most recently CTO of Adverum Biotechnologies; previously at AveXis/Novartis Gene Therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022004854/0000950170-22-004854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022004854/nktx-20220328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer